Breaking News, Collaborations & Alliances

Boehringer Ingelheim, LEO Pharma Partner to Commercialize & Develop SPEVIGO

Partnership will accelerate and broaden access to treatment for more patients with generalized pustular psoriasis, a rare skin condition.

Author Image

By: Charlie Sternberg

Associate Editor

Boehringer Ingelheim and LEO Pharma have signed an exclusive global license and transfer agreement to commercialize and advance the development of SPEVIGO (spesolimab), a humanized and selective monoclonal antibody that targets and blocks the activation of the interleukin-36 (IL-36) receptor—a key signaling pathway in the immune system implicated in the pathogenesis of several autoinflammatory diseases, including generalized pustular psoriasis (GPP). This partnership extends beyond GPP, with ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters